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There is solid evidence that complex traits can be caused by rare variants. Next-generation sequencing technologies are powerful tools
for mapping rare variants. Confirmation of significant findings in stage 1 through replication in an independent stage 2 sample is
necessary for association studies. For gene-based mapping of rare variants, two replication strategies are possible: (1) variant-based
replication, wherein only variants from nucleotide sites uncovered in stage 1 are genotyped and followed-up and (2) sequence-based
replication, wherein the gene region is sequenced in the replication sample and both known and novel variants are tested. The efficiency
of the two strategies is dependent on the proportions of causative variants discovered in stage 1 and sequencing/genotyping errors.With
rigorous population genetic and phenotypic models, it is demonstrated that sequence-based replication is consistently more powerful.
However, the power gain is small (1) for large-scale studies with thousands of individuals, because a large fraction of causative variant
sites can be observed and (2) for small- to medium-scale studies with a few hundred samples, because a large proportion of the locus
population attributable risk can be explained by the uncovered variants. Therefore, genotyping can be a temporal solution for replicating
genetic studies if stage 1 and 2 samples are drawn from the same population. However, sequence-based replication is advantageous if the
stage 1 sample is small or novel variants discovery is also of interest. It is shown that currently attainable levels of sequencing error only
minimally affect the comparison, and the advantage of sequence-based replication remains.Introduction
Currently there is worldwide interest in studying the role
of rare genetic variants in the etiology of complex traits.
A number of studies provide evidence that rare variants
are involved in the etiology of complex diseases and quan-
titative phenotypes.1–5 Indirect association mapping via
tagSNPs is underpowered to detect associations with rare
variants resulting from the weak correlations between
higher-frequency tagSNPs and rare variants.6 Instead,
direct association mapping through sequencing candidate
genes, exomes, or entire genomes needs to be applied,
where variants are discovered and tested. With the rapid
development of cost-effective next-generation sequencing
technologies such as Illumina HiSeq, ABI SOLiD, and
Roche 454 as well as target enrichment methods,
sequence-based genetic association studies of complex
traits have beenmade possible. For targeting large numbers
of genetic regions, hybrid-based methods such as on-array
or in-solution capture with NimbleGen or Agilent products
have been very beneficial.7–9 When targeting small genetic
regions is of interest, such as in candidate genes, capture
methods that use molecular inversion probes are advanta-
geous.9 Although sequencing only captured genetic
regions can be cost and time effective, high sequencing-
associated cost is still a concern, especially for sequencing
a large number of individuals at high coverage, which is
necessary to accurately detect rare variants.
Another constraint of the application of next-generation
sequencing to association studies is error rate. Relatively
high false variant discovery rates have been reported for1Department of Molecular and HumanGenetics, Baylor College of Medicine, H
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mina Solexa (6.3%) and ABI SOLiD (7.8%).10 Given these
concerns, there is interest in exploring alternative technol-
ogies after the variant discovery stage to extract informa-
tion from targeted genetic regions, such as customized
genotyping or the development of an exome genotyping
chip. Compared to next-generation sequencing platforms,
high throughput genotyping technologies can be more
cost effective and less error prone.
In this article, the plausibility of applying customized
genotyping and next-generation sequencing in replication
studies is explored from a combined genetic epidemiology
and population genetics perspective. In order to avoid
spurious or false positive findings in association mapping,
replicating significant associations discovered in an explor-
atory sample (stage 1)with an independentdata set (stage2)
is an indispensible part of every genetic association study. It
has been demonstrated that for the analysis of rare variants,
both single marker and multivariate methods used for the
analyzing common variants are underpowered because of
extreme allelic heterogeneity.6,11,12 Therefore, for mapping
rare variants, gene-based tests are usually performed, where
multiple rare variants in a gene region are jointly analyzed.
Many gene-based tests have been proposed such as the
combined multivariate and collapsing method (CMC),6
the weight sum statistic (WSS),12 and the test of aggregated
number of rare variants (ANRV).13 To replicate significant
findings in stage 1 studies, two different strategies can be
used. As a first strategy, only the variants at the nucleotide
sites uncovered from the original sample are followed up.
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only in the stage 2 sample will not be incorporated in the
replication study. This constitutes a replication in a ‘‘strict’’
sense, i.e., both the gene region and the variants uncovered
in the stage 1 sample are followed up in the replication
sample. When only variants uncovered in the stage 1
sample are of interest, genotyping is sufficient.Wewill refer
to this replication strategy as ‘‘variant-based.’’ An alterna-
tive strategy is to follow-up the entire gene region identified
in the stage 1 sample. For this design, analysis of the stage 2
sample is not restricted to the nucleotide sites uncovered in
stage 1. Variants from novel sites in the replication sample
are also assessed for their associations with the phenotype
of interest. We will refer to this design as ‘‘sequence-based’’
replication. With this strategy, sequencing the target gene
in the stage 2 sample is necessary. The efficiencies of the
two proposed strategies are compared.
The power of the two replication strategies is dependent
on the percentage of causal variant sites that were uncov-
ered for the gene region in the stage 1 sample. If the stage
1 sample is small, there can be an advantage to sequence-
based replication, because many low-frequency variants
may not have been observed. However, the difference
between variant-based and sequence-based replication
strategies will diminish if a majority of causal variants
can be uncovered in stage 1. Discovery of SNPs via popula-
tion-based samples has been addressed previously.14,15
However, in these studies the population genetic models
employed were overly simplistic; they did not incorporate
complex human demographic history and purifying selec-
tion, which are well-known factors that can affect rare
variant site frequency spectrums.16 A rigorous population
genetic model for Africans was used with parameters
estimated from sequence data.17 Together with realistic
phenotypic models motivated by complex traits, we inves-
tigate the probability of uncovering rare variants in the
context of case-control studies and demonstrate their
impact on the relative performances of sequence- and
variant-based replication.
Additionally, the relative power of the two replication
strategies will also be affected by the error rates of
next-generation sequencing and customized genotyping
technologies that are employed. To assess the impact of
sequencing error on the power of rare variant association
mapping, a data-based sequencing error model is used.
The parameters of the sequencing error model were
estimated according to reported false-positive and false-
negative variant discovery rates from commonly used
next-generation sequencing platforms.7,10,18,19
It is demonstrated through extensive simulations that
the sequence-based replication is more powerful than
variant-based replication for both small- and large-scale
studies. In the ideal scenario where sequencing and geno-
typing are both of perfect quality, for small-scale studies
with several hundred cases and controls, a large proportion
of variant nucleotide sites will not be uncovered. However,
uncovered rare variants in small-scale genetic studies can
account for more than 80% of the locus-specific popula-The Americantion attributable risk (PAR). Therefore, the power advan-
tage of sequencing can be small. For large-scale studies
with thousands of cases and controls, more than 90% of
the causative variant nucleotide sites can be uncovered
and nearly 100% of the locus PAR can be explained by
the uncovered rare variants. As a result, genotyping can
be a temporal solution for replicating stage 1 studies if
stage 1 and 2 samples are drawn from the same population.
Resequencing-based replication studies have an irreplace-
able advantage in that novel variants can be discovered.
This benefit is more pronounced when the stage 1 sample
is small. In the presence of sequencing errors, genotyping
errors, and unconverted genotyping assays, the relative
performances of two replication strategies remain largely
unchanged. We show that the power for sequence-based
association mapping is only slightly impacted by currently
attainable levels of error rates, for example, false-positive
rate/false-negative rates of 6.3%/1%10 or 10%/5%.19
In order to further illustrate the relative performances of
sequence-based and variant-based replication, phenotype
data on energy metabolism traits and sequence data from
the Dallas Heart Study on the ANGPTL3 (MIM 604774),
ANGPTL4 (MIM 605910), ANGPTL5 (MIM 607666), and
ANGPTL6 (MIM 609336) genes4,5 were analyzed with
CMC, WSS, and ANRV. The results provide solid support
for the simulation experiments.
Material and Methods
It is assumed that for a gene region of length L there are S variant
sites in the study population. The major allele at site s is denoted
by as, whereas the minor allele is labeled AS. The underlying L-site
genotype of an ‘‘individual’’ i is coded by a vector, i.e.,
X
!
i ¼ ðx1i ;/; xSi ; xSþ1i ;/; xLi Þ. Without loss of generality, sites
1;/; S are assumed to be variant sites in the population. Domi-
nant genotype coding is adopted for variant nucleotide sites, i.e.,
xsi ¼

1 if the genotype at nucleotide site s is Asas;or AsAs
0 otherwise
; s¼1;/; S:
The genotypes at monomorphic sites are identically coded as 0,
i.e., xsi ¼ 0; i ¼ Sþ 1;/;L.
According to the approach in Li and Leal,6 the collapsed geno-
type is introduced with an indicator function d(d), i.e.,
Xi ¼ d
 XL
s¼1
xsi > 0
!
:
The affection status for individual i is encoded by a binary
variable Yi, which takes value 1 if the individual is affected and
0 otherwise.
Probabilistic Model for Sequencing Errors
Because of the presence of sequencing errors, the observed geno-
type of an ‘‘individual’’ imay be different from the true underlying
genotype. The observed genotype from sequence data is given by
Z
!
i ¼ ðz1i ; z2i ;/; zLi Þ, where
zsi ¼

1 if the genotype at nucleotide site s is called as Asas;or AsAs
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The corresponding collapsed genotype Zi is similarly defined
as Zi ¼ dð
PL
s¼1
zsi > 0Þ.
Two types of sequencing error events are given probabilisti-
cally.10 First, a false-positive event is defined as zsi ¼ 1; xsi ¼ 0g

,
where a nonvariant genotype at nucleotide site s is falsely called a
variant. The error rate that corresponds to the false-positive event
is defined as the conditional probability es01 ¼ Pðzsi ¼ 1jxsi ¼ 0Þ.
Second, a false-negative event can be defined as zsi ¼ 0; xsi ¼ 1g

where a variant at site s is falsely called homozygous for the refer-
ence allele. Its error probability is defined as es10 ¼ Pðzsi ¼ 0jxsi ¼ 1Þ.
To measure and report sequencing error at rare variant nucleo-
tide sites, it is common to use false-positive discovery rate and
false-negative error rate,7,10,18,19 i.e.,
cFP ¼Pi;s dzsi ¼ 1; xsi ¼ 0P
i;s d

zsi ¼ 1
 ; cFN ¼Pi;s dzsi ¼ 0; xsi ¼ 1P
i;s d

xsi ¼ 1
 : (1)
Empirical estimates of false-positive and false-negative rates are
usually obtained by comparing next-generation sequencing with
less error-prone technologies, e.g., Sanger sequencing or custom-
ized genotyping.10,19
By using reported false-positive and false-negative rates, base-
pair error rates can be calculated as
FP¼
PL
s¼1
e01P

xsi ¼ 0

PL
s¼1
e01P

xsi ¼0
þð1 e10ÞPxsi ¼ 1; FN ¼
PL
s¼1
e10P

xsi ¼ 1

PL
s¼1
P

xsi ¼1
 : (2)
The observed number of carriers of rare variants at site s in cases
and controls are defined, respectively, as msA and m
s
U . For a sample
with RA cases and RU controls,m
s
A;m
s
U marginally follow binomial
distribution based upon the above sequencing error model,
i.e.,msA ¼
P
i
dðxsi ¼ 1;Yi ¼ 1Þ  BinomðRA; psAÞ, msU ¼
P
i
dðxsi ¼ 1;
Yi ¼ 0Þ  BinomðRU ; psU Þ, where parameters p!A ¼ ðpsAÞs¼1;/;L;
p
!
U ¼ ðpsU Þs¼1;/;L are given by
psA ¼ P

zsi ¼ 1 jYi ¼ 1
 ¼ ð1 e10Þ
3P

xsi ¼ 1 jYi ¼ 1
þ e013Pxsi ¼ 0 jYi ¼ 1
psU ¼ P

zsi ¼ 1 jYi ¼ 0
 ¼ ð1 e10Þ
3P

xsi ¼ 1 jYi ¼ 0
þ e013Pxsi ¼ 0 jYi ¼ 0
; s ¼ 1;/;L:
Models of Genotyping Errors
It is assumed that a set K of rare variant sites are uncovered in the
stage 1 sample. Rare variants from sites K are genotyped and fol-
lowed up in the stage 2 replication sample. Although the accuracy
for commercially available genotyping array is high, the error rate
for customized genotyping is not negligible.20 Additionally, assays
on customized probes may have a low conversion rate.
The observed locus genotype from genotyping data is denoted
by W
!
i ¼ ðw1i ;w2i ;/;wLi Þ, where
wsi ¼

1 if the genotype at nucleotide site s is called as Asas;
or AsAs
0 otherwise ; s˛K:
The corresponding collapsed genotype Wi is similarly defined.
For a converted assay, the genotyping error is traditionally mea-
sured as sample error rate (SER),21,22 i.e., SERs ¼ Pðwsi ¼ 1;
xsi ¼ 0jIsC ¼ 1Þ þ Pðwsi ¼ 0; xsi ¼ 1jIsC ¼ 1Þ; s˛K; where IsC is an indi-792 The American Journal of Human Genetics 87, 790–801, Decembcator for an assay being successful (e.g., converted with genotype
calls generated) at nucleotide site s. Similar to sequencing errors,
the genotyping error rates at converted probes are defined as:
f s01¼ P

wsi ¼ 1 j xsi ¼ 0; IsC ¼ 1

; f s10 ¼ P

wsi ¼ 0 j xsi ¼ 1; IsC ¼ 1

; S˛K:
(4)
To facilitate comparisons of the two replication strategies, an
error ratio ER is introduced to measure the relative error rates
for two types of sequencing and customized genotyping errors.
It is assumed that ER ¼Ps˛K f s10=PLs¼1es10 ¼Ps˛K f s01=PLs¼1es01:
When the two replication strategies are compared in the presence
of imperfect technologies, two error ratios are used, i.e., ER ¼ 1 or
ER ¼ 0.5. The rate of success for a given assay at site s, i.e.,
PðIsC ¼ 1Þ, is assumed to be 90%.
For a genotyped sample with RA cases and RU controls, the
observed counts of carriers of variants at each nucleotide site
are denoted byN
!
A ¼ ðnsAÞs˛K, N
!
U ¼ ðnsU Þs˛K . The counts at
nucleotide site s follow a binomial distribution marginally,
i.e., nsA  BinomðRA; qsAÞ, and nsU  BinomðRU ; qsU Þ . The parameters
q!A ¼ ðqsAÞs˛K ; q!U ¼ ðqsU Þs˛K are provided by
qsA ¼ P

zsi ¼ 1 jYi ¼ 1
 ¼ 1 f s103PIsC ¼ 1
3P

xsi ¼ 1 jYi ¼ 1
þ f s013PIsC ¼ 13Pxsi ¼ 0 jYi ¼ 1
qsU ¼ P

zsi ¼ 1 jYi ¼ 0
 ¼ 1 f s103PIsC ¼ 1
3P

xsi ¼ 1 jYi ¼ 0
þ f s013PIsC ¼ 13Pxsi ¼ 0 jYi ¼ 0
; s˛K:
(5)
Power Calculation for Sequence-Based
and Variant-Based Replication
Several test statistics formapping rare variants have beenproposed,
such as CMC,6 WSS,12 and ANRV.13 The ANRV test was developed
to detect associations with quantitative trait, but can be easily
generalized to the study of binary traits. These tests have been
shown to be more powerful than multivariate methods such as
Hotelling T2. Here, CMC,WSS, and ANRV are used in the compar-
isons of variant-based and sequence-based replication. The CMC
has a closed form exact distribution, which makes it
computationally efficient for candidate gene, exome-, and
genome-wide studies. The power of the permutation-based WSS
and ANRV methods were evaluated for small-scale candidate gene
studies. For all the scenarios evaluated, WSS and ANRV are more
powerful than CMC, but the comparisons for the two replication
strategies are largely unaffected by the choice of the test statistics.
For both sequence- and variant-based replicationwith CMC, the
association tests in both the stage 1 and stage 2 studies are imple-
mented via Fisher exact test, which compares rare variant carrier
frequencies between cases and controls. When the WSS and
ANRV statistic are used, to guarantee that type I error is well
controlled, p values are estimated empirically based upon 2000
permutations for each replicate. Because of the computation
intensity of estimating small empirical p values, the WSS and
ANRV were not used for the evaluation of power to replicate
large-scale studies.
The test statistics used for the stage 1 and sequence-based
stage 2 studies are denoted by TS1and Tseq, respectively. The
power of successfully replicating a true significant association
from the stage 1 study is investigated, i.e., PHA ðjTseqj >
z1aS2=2jjTS1j > z1aS1=2Þ, where aS1 and aS2 are significance levels
used for stage 1 and the replication study. Because the statistics
are conditionally independent given the parameters p
!
A and p
!
U ,
the following equation must be satisfied,er 10, 2010
PHA
 jTseq j > z1aS2=2; jTS1 j > z1aS1=2 j p!A; p!U
¼ PHA
 jTseq j > z1aS2=2 j p!A; p!UPHA jTS1 j > z1aS1=2 j p!A; p!U:
(6)
The power for variant-based replication is given
by PHA ðjTvarj > z1aS2=2jjTS1j > z1aS1=2Þ but unlike for sequence-
based replication, the test statistics Tvar, TS are not conditionally
independent. Under the alternative hypothesis, the distribution
of Tvar depends on K, which is the set of rare variant sites
uncovered in stage 1. Because it is impossible to enumerate the
parameter space of ð p!A; p!U ; q!A; q!U ;KÞ, an efficient Monte
Carlo algorithm was developed to calculate replication power for
both sequence-based and variant-based strategies (see Appendix).
For notational convenience, the ratio of total frequencies of
uncovered rare variants to the total frequencies of all locus rare
variants (including those that are not uncovered) is denoted
by fMAF ¼
P
s˛K
Pðxsi ¼ 1Þ=
PS
s¼1
Pðxsi ¼ 1Þ.
In addition, the ratio
fPAR ¼
X
s˛KXC
P

xsi ¼ 1 jYi ¼ 1
X
s˛C
P

xsi ¼ 1 jYi ¼ 1

; (7)
represents the proportion of locus PAR that can be ex-
plained by the uncovered causal variants. The probabilityP
s˛C Pðxsi ¼ 1jYi ¼ 1Þ is asymptotically equivalent to the epidemi-
ological definition of PAR, which is the reduction of disease
incidence rate that would be observed if the population were
unexposed, i.e., if there were no carriers of causative variants.
The power comparisons were performed for both the small- and
large-scale genetic studies. In order to have sufficient power to detect
associations, 250 cases/250 controls or 500 cases/500 controls were
used for both the stage 1 and 2 samples in a small-scale study. For
the scenario of a large-scale study, 2000 cases/2000 controls, as well
as 3500 cases/3500 controls were examined. For small-scale studies,
examples are given with significance levels aS1 ¼ aS2 ¼ 0.05.
The commonly accepted exome-wide significance level aS1 ¼ aS2 ¼
2.5 3 106 is used for large-scale genetic studies, which is based
upon Bonferroni corrections for testing 20,000 genes. The empirical
power for each scenario was estimated with 10,000 replicates.Simulations of Complex Demographic Models
and Selections
To compare relative efficiencies of sequence-based and variant-
based replication strategies, population genetic data were gener-
ated with forward time simulations.23 Genetic data for the African
population were generated. The parameters for demographic
changes and selections were estimated in Boyko et al.17 The
demographic change for the African population is described
with a two-epoch instant change model. Purifying selection was
also simulated, with u and 2u being the selective disadvantage of
heterozygous and homozygous new mutations. Scaled fitness
effect g ¼ 2Ncurru (where Ncurr is the current effective population
size) is assumed to follow a gamma distribution, i.e.,
g ¼ r; r  b
a
GðaÞr
a1expðbrÞ; where a ¼ 0:184; b ¼ 8200:
The model was shown to be parsimonious and fit the data well.
A mutation rate of mS ¼ 1.8 3 108 per nucleotide site per genera-
tion is assumed. Because the average length for human gene-
coding region is 1500 base pairs (bp) long,24,25 L ¼ 1500 bps wasThe Americanused in the simulation to specify the locus-scaled mutation rate.
Based upon the above parameter specification, 100 sets of rare
variant site frequencies were generated. As suggested by Kryukov
et al.,26 only nonsynonymous (NS) variants were used in the anal-
ysis in order to increase the signal to noise ratio and reduce the
negative impact of nonfunctional variants on power.
Generations of Phenotypic Model
Phenotypic effects of rare NS variants are assumed independent of
their fitness.24 Fifty percent of the rare NS variants (with MAF %
0.01) are randomly picked to be causal and affect the binary pheno-
type of interest. Based upon surveys of multifactorial diseases,27
two types of phenotypic models were considered. For the first
type of model, the genetic effects of causal variants are inversely
correlated with their MAFs. It is assumed that causal variants with
the smallest (or largest) MAFs (i.e., pmin or pmax) have largest (or
smallest) log odds ratio (log-OR) of bmax (or bmin), respectively.
For a causal variant with MAF pi, the log-OR follows the interpola-
tion relation: bi ¼ bmax þ (bmax  bmin)/(pmax  pmin)3(pi  pmin),
i ˛ C. The ORs for causal variants thus satisfy an exponential rela-
tionship with their MAFs. A choice of bmax ¼ log(10), bmin ¼ log
(2) was used. For the second type of model, each causal variant
has equal disease odds, which is given by bi ¼ log(3), i ˛ C. Under
both types of models, the affection status for an individual with
multisite genotype X
!
is assigned by the following model:
PðYi ¼ 1 j X!Þ ¼
exp

b0 þ
P
i˛C bsx
s
i

1þ expb0 þPi˛C bsxsi  : (8)
A baseline penetrance of 0.01 is assumed, which gives b0 ¼ log
(0.01/(1  0.01)).
Applications to the Dallas Heart Study Sequence Data
In order to illustrate the relative efficiency of sequence-based
versus variant-based replication strategies, a data set from DHS
was analyzed. The data set is a multiethnic population based
sample (1830 African Americans [AA], 601 Hispanics [H], 1045
European Americans [EA], and 75 individuals from other ethnic
groups) from Dallas County residents whose lipids and glucose
metabolism have been characterized and recorded.28,29 In order
to investigate how sequence variations in ANGTPL3, 4, 5, and 6
influence energy metabolism in humans, coding regions of the
four genes were sequenced via DNA samples obtained from 3551
participants in DHS.4 A total of 348 nucleotide sites of sequence
variations were uncovered in the four genes. Most of them are
rare and 86% of them have MAFs < 1%.4 Nine phenotypes were
measured and tested for their associations with rare genetic
variants, i.e., body mass index (BMI), diastolic blood pressure
(DiasBP), systolic blood pressure (SysBP), total cholesterol level
(TCL), low-density lipoprotein (LDL), high-density lipoprotein
(HDL), triglyceride (TG), very-low-density lipoprotein (VLDL),
and glucose. As a first analysis, to mimic the scenario of stage 1
study, individuals with quantitative trait values in the top and
bottom 10% of the phenotypic distributions were used to form
a case-control data set. Individuals with intermediate quantitative
trait values, i.e., in the range of 10%–35% and 65%–90%, were
used as a replication sample. Sequence-based and variant-based
replications were compared for the replication data set.
Among the identified significant results, the association
between TG level and rare variants in the ANGPTL4 gene was sup-
ported by in vitro functional studies and was replicated with an
independent data set.4,5 It is highly likely to be a true association.
Therefore, a second experiment was performed to estimate theJournal of Human Genetics 87, 790–801, December 10, 2010 793
Table 1. Discovery of Rare Variants in Small- and Large-Scale Genetic Studies
Proportion of Rare Variant Sites Uncovereda Proportiona
Number of Cases/Controls
in Stage 1 and 2 Samples All Causal
Locus PAR Explained
by Uncovered Causal
Rare Variants
Causal Variant Sites among
All Uncovered Rare Variant Sites
Variable Effect Phenotypic Model
250/250b 0.432 0.599 0.917 0.686
500/500b 0.524 0.687 0.950 0.645
2000/2000c 0.728 0.887 0.992 0.599
3500/3500c 0.808 0.943 0.996 0.572
Fixed Effect Phenotypic Model
250/250b 0.369 0.468 0.937 0.629
500/500b 0.455 0.547 0.960 0.591
2000/2000c 0.664 0.757 0.993 0.559
3500/3500c 0.751 0.827 0.995 0.538
a Rare variant data were simulated via African rare variant site frequency spectrums, and case control data sets were generated with variable and fixed effect
phenotypic models. A total of 10,000 replicates were generated and each reported value within the table was obtained by averaging over replicates where signif-
icant stage 1 results were obtained.
b Small-scale study: aS1 ¼ 0.05.
c Large-scale study: aS1 ¼ 2.5 3 106.power for replicating the association between TG and rare variants
in the ANGPTL4 gene. Individuals with TG levels in the range of
top 35% and bottom 35% were used to form a case-control
‘‘cohort.’’ 50% of the cases and 50% of the controls from the
‘‘cohort’’ were randomly selected as the data set for the stage 1
study. The remaining 50% of cases and controls are used as the
stage 2 replication sample. The process was repeated 1000 times,
and for each replicate, sequence-based and variant-based replica-
tion was performed. The fraction of significant stage 1 studies
that were successfully replicated in stage 2 was reported for the
comparison of two different replication strategies. Association
tests with CMC, WSS, and ANRV were performed.Results
Discovery Rate of Rare Variant Sites and Frequencies
Rare variant discovery rates were compared under the
assumption that sequencing data are of perfect quality
(Table 1). When sequencing is not perfect, the fractions
of uncovered rare variants will be lowered by false-negative
rate and additionally a portion of observed variants can be
false positives.
When a variable effect model is used, relatively low
proportions of variant nucleotide sites are uncovered
for small-scale studies. For example, in a sample of
250 cases/250 controls, 43.2% of all variant nucleotide
sites and 59.9% of causal variant nucleotide sites are
uncovered. On the other hand, a fairly large portion of
locus PAR (91.7%) can be explained by the uncovered vari-
ants.When a fixed effect model is employed, the results are
very similar (Table 1). A slightly lower portion of variants
can be uncovered but the uncovered variants explain
a higher fraction of locus PAR.
When a sample of 500 cases/500 controls was analyzed,
a higher proportion of variant sites are uncovered;794 The American Journal of Human Genetics 87, 790–801, Decembhowever, considerable fractions of rare variant sites in
the population are still not observed in the sample for
both fixed and variable effect models. For example, when
the fixed genetic effect model is used, only 45.5% of causal
variant sites are uncovered.
For an exome-wide significance level aS1 ¼ 2.5 3 106,
a much larger sample size is necessary to obtain sufficient
power to detect significant associations.26 Under the vari-
able genetic effect model, when a sample of 2000 cases
and 2000 controls was analyzed, for a gene region that
attains exome-wide significance, a much larger fraction
(72.8%) of rare variant nucleotide sites are present in the
data set, and nearly all (88.7%) causal nucleotide sites are
uncovered. These uncovered variants explain nearly 100%
of the locus PAR. Therefore, in principle, when a large stage
1 sample is analyzed, the advantage of sequencing for novel
SNPdiscoveries diminishes as longas the stage2 samples are
drawn from the same population. Similar results hold if
a fixed effect model is assumed for the binary phenotype.
Because affected individuals are enriched in a case-
control sample, nucleotide sites containing causal variants
have a much higher probability of being uncovered than
noncausal variant sites. For example, if a fixed effect model
is assumed, 62.9% of the sites uncovered are causal variant
sites for a sample of 250 cases and 250 controls. This frac-
tion is much higher than the proportions of causal variant
sites in the general population (50%).Power Comparisons for Sequence-Based
and Variant-Based Replication Strategies
The power was compared for sequence-based and
variant-based replication under different combinations of
false-positive/false-negative variant discovery rates, geno-
typing assay success rates, and error rates.er 10, 2010
Table 2. Power Comparisons of Sequencing-Based and Variant-Based Replication under Variable Effect Model
Ratesa Power for Replicationb
Number of Cases/Controls
in Stage 1 and 2 Samples False Positive False Negative Assay Succes Error Ratio Sequence-Based Variant-Based
250/250c 0 0 1 1 0.542 0.507
1% 4% 0.9 0.5 0.521 0.458
1 0.452
6.3% 1% 0.9 0.5 0.520 0.466
1 0.461
10% 5% 0.9 0.5 0.503 0.459
1 0.447
500/500c 0 0 1 1 0.731 0.708
1% 4% 0.9 0.5 0.719 0.675
1 0.667
6.3% 1% 0.9 0.5 0.718 0.674
1 0.674
10% 5% 0.9 0.5 0.701 0.672
1 0.661
2000/2000d 0 0 1 1 0.827 0.825
1% 4% 0.9 0.5 0.816 0.780
1 0.766
6.3% 1% 0.9 0.5 0.814 0.781
1 0.769
10% 5% 0.9 0.5 0.802 0.781
1 0.755
3500/3500d 0 0 1 1 0.899 0.898
1% 4% 0.9 0.5 0.893 0.870
1 0.863
6.3% 1% 0.9 0.5 0.893 0.868
1 0.865
10% 5% 0.9 0.5 0.886 0.874
1 0.858
a Significance levels for small-scale study: aS1 ¼ 0.05 and aS2 ¼ 0.05.
b Significance levels for large-scale study: aS1 ¼ 2.5 3 106 and aS2 ¼ 2.5 3 106.
c The impact of different combinations of false-positive/false-negative rate, assay success rate, and genotyping and sequencing error rate ratio on the replication
power is examined.
d The power was empirically estimated based upon 10,000 replicates.In the ideal scenario where both sequencing and custom-
izedgenotypingqualities areperfect, thepower for sequence-
based and variant-based replication is jointly affected by the
sample size, the proportions of rare variants uncovered and
the fractions of uncovered rare variant sites that contain
causal variants. For most of the examined scenarios, the
power of sequence-based replication is consistently higher
than variant-based replication when CMC is used for anal-
ysis. For example, under the variable effect model (Table 2),
for a sample size of 250 cases and 250 controls, the powerThe Americanfor sequence-based replication is 54.2% while the power of
variant-based replication is 50.7%. For large-scale genetic
studies, the power hardly differs between sequence- and
variant-based replication. This is because a large proportion
of variant sites are uncovered in the stage 1 sample, and
the uncovered variants account for nearly 100%of the locus
PAR. For example, for a gene that attains exome-wide signif-
icance in a sample of 2000 cases and 2000 controls, the
power for sequence- and variant-based replication are,
respectively, 82.7% and 82.5%.Journal of Human Genetics 87, 790–801, December 10, 2010 795
Table 3. Power Comparisons of Sequence-Based and Variant-Based Replication under Fixed Effect Model
Ratesa Power for Replicationb
Number of Cases/Controls
in Stage 1 and 2 Samples False Positive False Negative Assay Success Error Ratio Sequence-Based Variant-Based
250/250c 0 0 1 1 0.446 0.437
1% 4% 0.9 0.5 0.432 0.392
1 0.386
10% 1% 0.9 0.5 0.429 0.399
1 0.390
6.3% 5% 0.9 0.5 0.410 0.390
1 0.378
500/500c 0 0 1 1 0.666 0.658
1% 4% 0.9 0.5 0.650 0.619
1 0.607
6.3% 1% 0.9 0.5 0.652 0.623
1 0.613
10% 5% 0.9 0.5 0.632 0.619
1 0.600
2000/2000d 0 0 1 1 0.765 0.767
1% 4% 0.9 0.5 0.747 0.703
1 0.689
6.3% 1% 0.9 0.5 0.746 0.705
1 0.694
10% 5% 0.9 0.5 0.724 0.700
1 0.669
3500/3500d 0 0 1 1 0.875 0.878
1% 4% 0.9 0.5 0.872 0.841
1 0.834
6.3% 1% 0.9 0.5 0.870 0.845
1 0.835
10% 5% 0.9 0.5 0.856 0.843
1 0.825
a Significance levels for small-scale study: aS1 ¼ 0.05 and aS2 ¼ 0.05.
b Significance levels for large-scale study: aS1 ¼ 2.5 3 106 and aS2 ¼ 2.5 3 106.
c The impact of different combinations of false-positive/false-negative rate, assay success rate, and genotyping and sequencing error rate ratio on the replication
power is examined.
d The power was empirically estimated based upon 10,000 replicates.The power for sequence- and variant-based replication is
negatively impacted by sequencing and genotyping errors.
The impact of sequencing error is small. If the fixed effect
model is assumed (Table 3), for a sample size of 250 cases
and 250 controls, the power of sequenced-based replica-
tion is 44.6% in the absence of sequencing errors; when
a false-positive rate of 10% and a false-negative rate of
5% are assumed, the power drops to 41.0%. Although
a lower error rate is assumed for customized genotyping,
the advantage of sequence-based replication remains. For796 The American Journal of Human Genetics 87, 790–801, Decembinstance, in this scenario, for a genotyping call rate of
90% and an error rate ratio of 0.5, the power for variant-
based replication is 39.0%.
Comparisons of two replication strategies were also
made when WSS and ANRV were used for analysis of
both the stage 1 and 2 data sets (Table S1 available online).
Although the power is consistently higher for theWSS and
the ANRV than for the CMC, the relative performances for
sequence-based and variant-based replication are similar
in most situations. One noticeable difference is thater 10, 2010
Table 4. Analyses of Sequence Data from the ANGPTL3, 4, 5, and 6 Genes
p Values Proportion Ratio Number of Rare Variants Observed
Trait
Stage 1 Analysisa
(CMC/WSS/ANRV)
Sequence-Based
Replicationb
(CMC/WSS/ANRV)
Variant-Based
Replicationb
(CMC/WSS/ANRV)
Nucleotide
Sites Uncovered
in Stage 1
Rare Variant Freq
in Stage 1 Sample/
Rare Variant Freq.
in Entire Sample
Sequence-
Based
Replication
Variant-
Based
Replication
ANGPTL3
TCL 0.028/0.022/0.033 0.522/0.493/0.534 0.726/0.724/0.845 0.30 0.87 46/51 39/40
ANGPTL4
LDL 0.021/0.025/0.022 0.272/0.218/0.194 0.508/0.473/0.387 0.35 0.94 78/62 70/60
TG 0.027/0.022/0.009 0.025/0.016/0.019 0.039/0.028/0.027 0.26 0.92 77/51 69/46
VLDL 0.037/0.024/0.011 0.031/0.020/0.024 0.031/0.023/0.025 0.26 0.92 75/51 69/46
ANGPTL5
BMI 0.029/0.021/0.033 0.464/0.407/0.670 0.451/0.423/0.661 0.5 0.95 67/71 63/67
HDL 0.025/0.022/0.017 1.0/0.959/0.729 0.772/0.760/0.947 0.5 0.95 63/66 61/60
ANGPTL6
BMI 0.001/0.001/0.001 0.909/0.874/0.823 0.794/0.774/0.729 0.21 0.78 42/40 33/30
a For each phenotype analyzed, individuals with QTVs from the top and bottom 10% were used as a stage 1 sample.
b Individuals with QTVs in the range of 10%–35% and 65%–90% were used as the replication sample.sequencing error tends to have a slightly more negative
impact on power for studies via the WSS. The power for
variant-based replication can be even higher than
sequence-based replication when WSS is implemented
for data analysis. For example, for a sample of 250 cases
and 250 under the fixed effect model, where the false-posi-
tive rate is 10%, the false-negative rate is 5%, and error rate
ratio ER ¼ 0.5, the power for sequence-based replication
(53.3%) is even lower than that for variant-based replica-
tion (54.7%).Applications to the Dallas Heart Study Data
For the first analysis, the stage 1 and 2 data from the
ANGPTL3, 4, 5, and 6 genes are analyzed. Although a small
sample size (individuals with trait values in the top and
bottom 10%) was used for the stage 1 study, multiple
(novel) associations were detected with the CMC and
WSS (Table 4), i.e., (1) TCL with ANGPTL3 (pCMC ¼ 0.028,
pWSS ¼ 0.022, pANRV ¼ 0.033), (2) LDL with ANGPTL4
(pCMC ¼ 0.021, pWSS ¼ 0.025, pANRV ¼ 0.022), (3) TG with
ANGPTL4 (pCMC ¼ 0.027, pWSS ¼ 0.022, pANRV ¼ 0.009),
(4) VLDLwithANGPTL4 (pCMC¼ 0.037, pWSS¼ 0.024, pANRV¼
0.011, (5) BMI with ANGPTL5 (pCMC¼ 0.029, pWSS¼ 0.021,
pANRV ¼ 0.033), (6) HDL with ANGPTL5 (pCMC ¼ 0.025,
pWSS ¼ 0.022, pANRV ¼ 0.017), and (7) BMI with ANGPTL6
(pCMC¼ 0.001, pWSS¼ 0.001, pANRV¼ 0.001). Among these,
the association between BMI and ANGPTL6 is significant
even after Bonferroni correction for testing multiple geno-
types and phenotypes. For most of the analyses, approxi-
mately 25%–40% of the nucleotide sites observed in the
entire DHS sample are also observed in stage 1. The stage
2 replication sample consists of individuals with less
extreme quantitative trait values. To ensure that the power
of the stage 2 sample is adequate, the stage 2 samples areThe Americanchosen to be larger than the stage 1 sample size. Two of
the seven identified associations in the stage 1 sample
were successfully replicated by both sequence- and
variant-based replication, i.e., associations between TG
and ANGPTL4 as well as between VLDL and ANGPTL4.
For both associations, sequence-based replication has
slightly smaller p values.
For the second analysis, the empirical power for repli-
cating the validated association between TG and rare
variants in ANGPTL4 gene was compared. When the
CMC is used, the empirically estimated power for
sequence-based and variant-based replication is 65.3%
and 62.7%, respectively. The power for sequence-based
replication is only slightly better. This is very compatible
with observations from simulated data. When the WSS
and ANRV are used, estimated power is greater but the
relative performances (69.3% versus 67.0% for WSS and
68.2% versus 64.4% for ANRV) are concordant.Discussion
In this article, sequence-based replication and variant-
based replication for complex trait rare variant association
studies were compared with a rigorous population genetic
framework. It is demonstrated that in the ideal scenario
where sequencing and genotyping are both of perfect
quality, sequence-based replication is consistently more
powerful. However, because the uncovered variants can
account for a large proportion of locus PAR even for stage
1 studies with only a few hundred samples, the advantage
in power can be very small if stage 1 and stage 2 samples are
drawn from the same population. The power of sequence-
and variant- based replication studies is negatively im-
pacted by sequencing and genotyping errors. For currentlyJournal of Human Genetics 87, 790–801, December 10, 2010 797
attainable levels of sequencing errors, the impact is
minimal, and the advantage of using sequence-based repli-
cation studies remains.
It has been found previously that rare variants tend to be
population specific.27 Many studies have suggested that
disease-associated variants in different populations can
have very different frequencies. For example, the E40K
variant in ANGPTL4 gene was shown to be associated
with TG levels. The MAF for E40K is approximately 3%
in European-Americans but is very rare in African-Ameri-
cans and Hispanics.4 These differences can be observed
in even more closely related populations, for example,
rare variants in CFTR (MIM 602421), BRCA1 (MIM
113705), and BRCA2 (MIM 600185) genes have higher
frequencies in the Ashkenazi Jewish population compared
to other European Jewish populations such as Sephardic
Jews and also to non-Jewish populations.30,31 Population-
specific diversity of variant frequencies and sites is believed
to be more pronounced for rare variants than for common
variants because rare variants tend to be younger and occur
more recently in human history.27 When stage 2 samples
are drawn from a different population than the stage 1
samples, the variant-based replication studies may be at
a disadvantage. Given that the demographic and selection
models incorporating complex migration and admixtures
are limited,17 simulation studies for variant discovery
with multiethnic samples still remain to be explored. Eval-
uating the benefits and drawbacks of replication studies
with samples from different populations will be very
important.
This article also provides a model for incorporating
sequencing error uncertainties into downstream associa-
tion analysis. Some of the error rates discussed in this
article (e.g., FP ¼ 6.3%, FN ¼ 1%) are attained when a
saturated coverage depth is used. With the maturation of
next-generation sequencing technologies, as well as the
development of more sophisticated genotype calling algo-
rithms, such as using pooled population samples,32 even
lower rates should be attainable in the near future. For
currently attainable levels of sequencing errors, their
impact on the power of rare variant association mapping
is minimal.
The WSS is more sensitive to sequencing errors than the
CMC and ANRV, because it assigns higher weights to
lower-frequency variants.12 Sequencing error can create
false-positive variant sites that have very low allele
frequencies.32 Therefore, in some scenarios with higher
sequencing error rates, when analysis is performed with
WSS, sequence-based replication can be less powerful
than variant-based replication.
Although the error model for Sanger sequencing is well
known, the error model for next-generation sequencing
has not been extensively evaluated.19,33,34 Because of the
paucity of information on error rate estimation, our error
model assumes equal error rates across different nucleotide
sites. This is certainly an oversimplification. In practice, for
different frequency bins, different false-positive and false-798 The American Journal of Human Genetics 87, 790–801, Decembnegative discovery rates can be expected. The proposed
error model can be refined and applied to specific
frequency bins when corresponding false-positive and
false-negative rate estimates become available. Various
studies have shown that nonrandom systematic errors
exist and cannot be ignored.10,32 The systematic errors
can be dependent on the genetic context of the variants.
However, given that the main interest lies in gene-based
association mapping, modeling error rate variation across
different nucleotide sites may not be a necessity because
only their overall impact in the gene region needs to be
assessed. In particular, when the CMC method is used,
the power is affected only by total number of errors, but
not by the nucleotide sites where those errors occur. The
error rates used in our model can be taken as locus
averages. When comparing variant-based replication, gen-
otyping error rates are assumed to be equal or lower than
sequencing error rates. It can be argued that this is sensible
for two reasons. First, genotyping technology is more
mature than sequencing, so it tends to have a lower error
rate per base pair. Second, because customized genotyping
is performed only at nucleotide sites with putative poly-
morphisms, it is less error prone than sequencing
where SNP discovery and genotype calling are performed
simultaneously.
Population genetic data were generated through forward
time simulations. Both demographic change and purifying
selections are known to be important factors affecting rare
variant site frequency spectrums. Therefore, they are both
modeled and incorporated in the simulations. Two types of
phenotypic models were considered. According to surveys
on multifactorial disorders, most of the uncovered disease-
causative rare variants have ORs between 2 and 4.27
Although results are shown only for OR ¼ 3, OR ¼ 2 and
OR ¼ 4 were also investigated, and the conclusions remain
the same. On the other hand, variable effect models also
have empirical support. It has been observed that lower-
frequency rare genetic variants tend to have larger disease
odds compared tomore frequent variants.11,27 There is also
evidence that highly penetrant rare genetic variants may
be involved in the etiology of complex traits.35,36 Because
amajority of rare variants have very low frequencies, when
ORmax ¼ 10, ORmin ¼ 2 is used, most of the uncovered rare
variants have ORs % 4. The results of comparisons of
replication study designs remain valid and robust under
both types of phenotypic models.
In the examples discussed in this article, two different
significance levels are used in stage 1 (aS1 ¼ 0.05, aS1 ¼
2.5 3 106). These significance levels are chosen for illus-
trative purposes. In practice, the significant levels used
are dependent on the effective number of tests that can
be performed. Currently for exome data where analysis is
performed on a gene-by-gene basis, it is recommended to
use an a level of 2.53 106. This significance level is based
on the Bonferroni correction for testing 20,000 genes.
Because there is little linkage disequilibrium between rare
variants in different genes, a Bonferroni correction willer 10, 2010
not be overly conservative. If the analysis is not only per-
formed on the gene level but pathway analysis is also per-
formed, a more stringent a level is necessary. The choices
for stage 2 significance levels are also for illustrative
purposes. If gene(s) are found to be associated with a trait
of interest with an a level that adequately controls the
FWER in stage 1, it is not necessary to use the same strin-
gent a level to replicate the association. The appropriate
significance level is determined by the number of tests
performed in stage 2.
In order to proceed to replication, the stage 1 study must
be sufficiently powered to detect associations. For the
examples given in this article, the smallest sample size
shown is 250 cases/250 controls. Examples with smaller
sample sizes are not shown because if a realistic complex
trait model is used they will not be adequately powered.
Given the cost of whole-exome sequencing studies, some
existing studies use very small sample sizes. These studies
are mostly for exploratory purposes and targeted at
Mendelian disorders.7,8,37–39 They will be extremely under-
powered for detecting associations with rare variants
involved in complex disease etiologies.
Sequencing has an irreplaceable advantage over geno-
typing, which is to discover novel genetic variants. The
human population has experienced complex patterns of
demographic expansion and purifying selection.4,16 Large
numbers of very rare variant nucleotide sites exist. Based
upon observations from our extensive simulations and
real data, for moderate-sized stage 1 studies, only a limited
proportion of rare variant nucleotide sites can be uncov-
ered. Identifying and cataloging rare variants themselves
can be of great importance in genetic studies. Novel rare
causal variants that are uncovered will help enhance the
understanding of the genetic architecture of complex
traits. They can also be useful for risk prediction and
personalized medicine. And therefore, even if a gene is
implicated in disease etiology via variant-based replication,
it can still be beneficial to sequence the region in the stage
2 sample in order to uncover potential novel causal vari-
ants. For large-scale genetic studies with thousands of cases
and controls the yield of sequencing, the stage 2 sample
can be low, because the majority of the disease-causative
variants may have been identified in stage 1.
For both stage 1 and 2 studies, it is important to be able
to control for population substructure/admixture. If data
from genome-wide association studies (GWAS) are avail-
able for the stage 2 sample, it can be used to control for
population substructure/admixture. If GWAS data are not
available, customized genotyping can be advantageous to
targeted sequencing in that it can be used to genotype
additional unlinked markers to control for population
substructure/admixture.
With the rapid large-scale application of next-generation
sequencing, understandings of genetic etiologies of rare
variants will advance to an unprecedented level. Replica-
tions of significant findings will be an indispensible part
of every genetic study. Sequence-based replication forThe Americanboth small-scale and large-scale genetic studies is advanta-
geous andwill eventually be affordable and widely applied.
In the meantime, variant-based replication can be a
temporal cost-effective solution for replications of genetic
studies and will greatly accelerate the process of identi-
fying disease-causative variants.Appendix A
Algorithm 1: An Efficient Algorithm for Estimating
Power for Gene-Based Replication
(1) Randomly pick one set of generated variant site
frequencies and select 50% of the rare variant sites as
causal, which effects the phenotype of interest.
(2) According to the chosen haplotype pool, the set of
causal variant sites, and error model, the variant site carrier
frequencies in cases and controls, i.e., p
!
A; p
!
U , are deter-
mined by formula (3). A stage 1 data set with OA cases
and OU controls and replication data set with RA cases
and RU controls are generated according to p
!
A and p
!
U .
(3) Repeat steps (1) and (2)N times, and for each iteration i,
the test statistics TS1i ;T
seq
i are computed for the stage 1 data
set and the replication data set.
(4) The power of replicating a significant association
via gene-based replication, i.e., PðjTseqj > z1aS2=2jjTS1j >
z1aS1=2Þ, can be approximated bybP jTseq j > z1aS2=2 j jTS1 j > z1aS1=2
¼ 1=N
P
i d
 jTS1i j > z1aS1=2; jTseqi j z1aS2=2
1=N
P
i d
 jTS1i j > z1aS1=2 ;
where the numerator and denominator are consistent
estimators for PðjTS1j > z1aS1=2; jTseqj > z1aS2=2Þ and
PðjTS1j > z1aS1=2Þ, respectively.Algorithm 2: A Similar Algorithm for Estimating
Power for Variant-Based Replication Is Given Below
(1) Randomly pick one set of generated variant site
frequencies and select 50% of the variant sites as causal,
which affects the phenotype of interest.
(2) According to the chosen haplotype pool, the set of
causal variant sites, and error model, the variants site
carrier frequencies in cases and controls p
!
A; p
!
U are deter-
mined by formula (3). A stage 1 data set with OA cases and
OU controls is generated according to p
!
A and p
!
U . The set
of variant nucleotide sites in the stage 1 sample is denoted
by K. A corresponding replication data set of RA cases
and RU controls is generated based upon q
!
A ¼ ðqsAÞs˛K;
q!U ¼ ðqsUÞs˛K given by formula (5).
(3) Repeat steps (1) and (2)N times, and for each iteration i,
the test statistics TS1i ;T
var
i are computed for the stage 1 data
set and the replication data set.
(4) The power of replicating a significant association via
variant-based replication, i.e., PðjTvarj > z1aS2=2jjTS1j >
z1aS1=2Þ, can be approximated byJournal of Human Genetics 87, 790–801, December 10, 2010 799
bP jTvar j > z1aS2=2 j jTS1 j > z1aS1=2
¼ 1=N
P
i d
 jTS1i j > z1aS1=2; jTvari j > z1aS2=2
1=N
P
i d
 jTS1i j > z1aS1=2 ;
where the numerator and denominator are, respectively,
consistent estimators for PðjTS1j > z1aS1=2; jTvarj > z1aS2=2Þ
and PðjTS1j > z1aS1=2Þ.Supplemental Data
Supplemental Data include one table and can be found with this
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